BrainSee™ — The Central Intelligence Platform for Alzheimer’s Drug DevelopmentIdentify the right patients, at the right stage, for the right trial, using FDA-approved, MRI-based prognostics.
The Challenge
CNS trials fail because:
Patients are difficult to recruit
Cohorts are biologically heterogeneous
Endpoints lack sensitivity
Timelines and costs escalate
The BrainSee Solution
Objective, MRI-based risk stratification — before irreversible decline.
BrainSee predicts risk to Alzheimer’s from standard MRI, enabling:
Earlier-stage enrollment
Cleaner cohorts with higher drug signal
Quantitative, repeatable endpoints
Why Leading Pharma Uses BrainSee
Increase Probability of Success
- Precision cohort selection
- Reduced placebo dilution
- Stronger efficacy signal
Accelerate Development
- Faster screening
- Earlier go/no-go decisions
- Clearer regulatory narratives
Lower Trial Cost
- Fewer screen failures
- Smaller, more powerful trials
- Reduced extensions and delays
Regulatory-Ready
- FDA-approved SaMD
- Explainable, standardized outputs
- Designed for submissions and audits
Built for Scale
- Works with standard MRI (no new hardware)
- PACS, EMR, trial-workflow compatible
- Proven across 2,000+ patients, 23 clinical sites
Designed for Phase II–IV CNS trials
- Seamless integration with existing protocols
- Continuous support and optimization
Engagement Model
Pilot
Trial Integration
Longitudinal Monitoring
